@aleksanderkrag.bsky.social
To Screen—or not to screen for
for advanced steatotic liver disease that’s the question?
Our new @lancetgastrohep.bsky.social
review re-examines Wilson & Jungner (1968), weighs today’s evidence, and proposes 2025 screening criteria
@Stine Johansen
authors.elsevier.com/c/1lRV98nByr...
New Review - Screening for advanced steatotic liver disease
www.thelancet.com/journals/lan...
#LiverSky #MedSky @aleksanderkrag.bsky.social
Fig. 4: The bidirectional linking of factors that predispose to steatotic liver disease.
APRIL ISSUE | Our Featured PERSPECTIVE is on "The steatotic liver disease burden paradox: unravelling the key role of alcohol"
www.nature.com/articles/s41...
#Liversky
Steatotic liver disease burden paradox, inspired by the Perspective on p281.
Our APRIL ISSUE is live! Steatotic liver disease and alcohol, disorders of gut–brain interaction, coeliac disease, advanced chronic liver disease, and much more!
www.nature.com/nrgastro/vol...
🧪 New findings published in @jhepatology.bsky.social JHEP reports benchmarking several biomarkers and combinations hereof show soluble TREM2, PRO-C3 & HOMA-IR effectively reflect histological disease activity in MASLD/MASH patients in response to treatment.
doi.org/10.1016/j.jh...
Why do some patients remain healthy while others develop severe liver complications despite having the exact same genetic mutation in Alpha-1 Antitrypsin Deficiency?
Proud of being part of this project - Deep Visual Proteomics at single cell level
👉in @nature.com
www.nature.com/articles/s41...
Check out the “Steatotic Liver Disease Burden Paradox “
pubmed.ncbi.nlm.nih.gov/39639157/
Our newdata show 38% of individuals with SLD are reclassified over 2 years ‼️
Over 60% with MetALD/ALD and 38% with MASLD change subclass.
This highlights that alcohol use and metabolic risk need regular reassessment, incl. for clinical trial eligibility 🧐
Link: www.cghjournal.org/article/S154...
We made the cover of Hepatology 👏👏
@aleksanderkrag.bsky.social #LiverSky
journals.lww.com/hep/fulltext...
In today’s #readoftheweek📚 learn why accurate quantification of alcohol intake is crucial in the clinical phenotyping of patients with #steatoticliverdisease & when designing clinical trials.
Read now: www.jhep-reports.eu/article/S258...
🙏 @aleksanderkrag.bsky.social @majathiele.bsky.social et al.
#EASL Studio season 8 starts next week, we will discuss Steatotic Liver Disease - how the current breakthroughs will transform clinical practice. Want to stay updated join us.!
easl.eu/easl-studio-...
AlbTrial Update
🏥 70 out of 240 included
But what is AlbTrial?
AlbTrial is one of the most ambitious RCTs in the field of decompensated cirrhosis.
🔗 bmjopen.bmj.com/content/bmjo...
🧵below
Annual General Assembly in MicrobPredict #liversky #cirrhosis
What impact do reporting discrepancies in alcohol intake have on the estimated prevalence of MetALD and alcohol-related liver disease?
@aleksanderkrag.bsky.social and colleagues discuss…
www.thelancet.com/journals/lan...
#GastroSky #MedSky
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD - MASLD VS MetALD/ALD is not 10:1 - more likely 1:1😳
- The Lancet Gastroenterology & Hepatology www.thelancet.com/journals/lan...
Joined a great meeting in Helsinki recently and had the pleasure of seeing but not understanding the new nomenclature of Steatotic liver disease in Finnish😀
16.01.2025 17:28 — 👍 3 🔁 0 💬 0 📌 02025 is the perfect year to take your career to the next level🚀
There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force.
Apply by 20 January: easl.eu/leadership25
#LiverSky
Two days of finalizing the narrative and recommendations of the second EASL @thelancet.bsky.social Commission in Geneva. Now we write the report! @aleksanderkrag.bsky.social
10.12.2024 18:39 — 👍 11 🔁 3 💬 0 📌 1
EASL Governing Board meeting - working for the community❤️
👉SLD and LCS summits
👉EASL schools / what and where?
👉EiC @JHepatology @JHEP_Reports new initiatives🤩
👉 X vs @bluesky ?
👉AI Task Force
👉#EASLCongress 2025 Amsterdam
👉Register grants
👉Global collaboration
@EASL @AASLD MASTERCLASS in beautiful Savannah ❤️
Gathering of next generation of leaders in hepatology🤩🤩
👉team science
👉building a team
Networking
Ever heard about the “Steatotic Liver Disease burden paradox”?
Check it out 👇👇👇
Perspective in
@natureportfolio.bsky.social
rdcu.be/d2wcV
Remember deadline for abstract EASLCongress 2025 in Amsterdam
December 3rd !!
After a successful #TLM24 AASLD in San Diego - thanks Ray Kim and Paul Kwo for a fantastic hospitality at @stanfordpress.bsky.social
23.11.2024 00:44 — 👍 1 🔁 0 💬 0 📌 0
